Patents by Inventor Kakuji Torigoe
Kakuji Torigoe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140336364Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.Type: ApplicationFiled: July 31, 2014Publication date: November 13, 2014Inventors: Haruki OKAMURA, Tadao TANIMOTO, Kakuji TORIGOE, Toshi KUNIKATA, Mutsuko TANIGUCHI, Keizo KOHNO, Masashi KURIMOTO
-
Patent number: 7758853Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.Type: GrantFiled: August 12, 1999Date of Patent: July 20, 2010Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Haruki Okamura, Tadao Tanimoto, Kakuji Torigoe, Toshi Kunikata, Mutsuko Taniguchi, Keizo Kohno, Masashi Kurimoto
-
Patent number: 7666403Abstract: The present invention has objects to provide a mutant interferon-? protein having a higher anti-viral and anti-tumor activity and to provide an agent for susceptive diseases, which contains the mutant interferon-? protein as an effective ingredient; and solves the above objects by providing a mutant protein which has an amino acid sequence of human interferon-? subtype ?8 represented by any one of SEQ ID NOs:1 to 3, where the arginine residue at the 145th has been replaced with leucine, isoleucine, or valine residue; the alanine residue at the 146th has been replaced with asparagine or serine residue; and the methionine residue at the 149th has been replaced with tyrosine residue; and an agent for susceptive diseases, containing the mutant protein.Type: GrantFiled: November 9, 2005Date of Patent: February 23, 2010Assignees: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Tadanori Mayumi, Yasuo Tsutsumi, Shinsaku Nakagawa, Madoka Taniai, Kakuji Torigoe, Masashi Kurimoto
-
Publication number: 20090311218Abstract: The present invention has objects to provide a mutant interferon-? protein having a higher anti-viral and anti-tumor activity and to provide an agent for susceptive diseases, which contains the mutant interferon-? protein as an effective ingredient; and solves the above objects by providing a mutant protein which has an amino acid sequence of human interferon-? subtype ?8 represented by any one of SEQ ID NOs:1 to 3, where the arginine residue at the 145th has been replaced with leucine, isoleucine, or valine residue; the alanine residue at the 146th has been replaced with asparagine or serine residue; and the methionine residue at the 149th has been replaced with tyrosine residue; and an agent for susceptive diseases, containing the mutant protein.Type: ApplicationFiled: November 9, 2005Publication date: December 17, 2009Applicant: KABUSHIKI KAISHA HAYASHIBARTA SEIBUTSU KAGAKI KAGAKU KEBKYUJOInventors: Tadanori Mayumi, Yasuo Tsutsumi, Shinsaku Nakagawa, Madoka Taniai, Kakuji Torigoe, Masashi Kurimoto
-
Patent number: 7355014Abstract: A human IFN-? inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-? inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-?, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.Type: GrantFiled: October 16, 2006Date of Patent: April 8, 2008Assignee: Kabushiki Kaisha Hay Ashibara Seibutsu Kagaku KenkyujoInventors: Shimpei Ushio, Kakuji Torigoe, Todao Tanimoto, Haruki Okamura, Masashi Kurimoto, Shigeharu Fukuda, Toshio Kunikata, Mutsuko Taniguchi, Keizo Kohno
-
Publication number: 20070031403Abstract: A human IFN-? inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-? inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-?, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.Type: ApplicationFiled: October 16, 2006Publication date: February 8, 2007Inventors: Shimpei Ushio, Kakuji Torigoe, Todao Tanimoto, Haruki Okamura, Masashi Kurimoto, Shigeharu Fukuda, Toshio Kunikata, Mutsuko Taniguchi, Keizo Kohno
-
Patent number: 7141393Abstract: Disclosed are a receptor protein which recognize a novel cytokine, i.e., interleukin-18, a monoclonal antibody specific to the protein, and uses thereof. The receptor protein is useful as pharmaceutical to treat and prevent autoimmune and allergic disease because it suppresses and regulates excessive immunoreaction. The monoclonal antibody specifically reacts with interleukin-18, exhibiting efficacy in purification, detection and inhibition of interleukin-18.Type: GrantFiled: December 22, 1997Date of Patent: November 28, 2006Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kakuji Torigoe, Shimpei Ushio, Toshio Kunikata, Masashi Kurimoto
-
Patent number: 7135458Abstract: A human IFN-? inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel IFN-? inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with IFN-?, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.Type: GrantFiled: November 21, 2000Date of Patent: November 14, 2006Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Shimpei Ushio, Kakuji Torigoe, Todao Tanimoto, Haruki Okamura, Masashi Kurimoto, Shigeharu Fukuda, Toshio Kunikata, Mutsuko Taniguchi, Keizo Kohno
-
Publication number: 20050191303Abstract: The objects of this invention are to provide a substance which suppresses the physiological activities of IL-18 through binding to IL-18, uses of the substance, and a DNA encoding the substance; this invention attains these objects by providing an IL-18-binding protein comprising a specific amino acid sequence, a DNA encoding this protein, and an IL-18-suppressor as well as agent for susceptive diseases containing as an effective ingredient this IL-18-binding protein.Type: ApplicationFiled: June 28, 2004Publication date: September 1, 2005Applicant: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJOInventors: Kakuji Torigoe, Madoka Taniai, Masashi Kurimoto
-
Publication number: 20040253303Abstract: Disclosed is a genomic DNA encoding a polypeptide capable of inducing the production of interferon-&ggr; by immunocompetent cells. The genomic DNA efficiently expresses the polypeptide with high biological activities of such as inducing the production of interferon-&ggr; immunocompetent cells, enhancing killer cells' cytotoxicity and inducing killer cells' formation, when introduced into mammalian host cells. The high biological activities of the polypeptide facilitate its uses to treat and/or prevent malignant tumors, viral diseases, bacterial infectious diseases and immune diseases without serious side effects when administered to humans.Type: ApplicationFiled: December 9, 2003Publication date: December 16, 2004Applicant: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJOInventors: Takanori Okura, Kakuji Torigoe, Masashi Kurimoto
-
Patent number: 6790442Abstract: Disclosed is a genomic DNA encoding a polypeptide capable of inducing the production of interferon-&ggr; by immunocompetent cells. The genomic DNA efficiently expresses the polypeptide with high biological activities of such as inducing the production of interferon-&ggr; by immunocompetent cells, enhancing killer cells' cytotoxicity and inducing killer cells' formation, when introduced into mammalian host cells. The high biological activities of the polypeptide facilitate its uses to treat and/or prevent malignant tumors, viral diseases, bacterial infectious diseases and immune diseases without serious side effects when administered to humans.Type: GrantFiled: January 10, 2000Date of Patent: September 14, 2004Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Takanori Okura, Kakuji Torigoe, Masashi Kurimoto
-
Publication number: 20030190318Abstract: Disclosed are a receptor protein which recognize a novel cytokine, i.e., interleukin-18, a monoclonal antibody specific to the protein, and uses thereof. The receptor protein is useful as pharmaceutical to treat and prevent autoimmune and allergic disease because it suppresses and regulates excessive immunoreaction. The monoclonal antibody specifically reacts with interleukin-18, exhibiting efficacy in purification, detection and inhibition of interleukin-18.Type: ApplicationFiled: December 22, 1997Publication date: October 9, 2003Inventors: KAKUJI TORIGOE, SHIMPEI USHIO, TOSHIO KUNIKATA, MASASHI KURIMOTO
-
Patent number: 6600022Abstract: Disclosed are a receptor protein which recognize a novel cytokine, i.e., interleukin-18, a monoclonal antibody specific to the protein, and uses thereof. The receptor protein is useful as pharmaceutical to treat and prevent autoimmune and allergic disease because it suppresses and regulates excessive immunoreaction. The monoclonal antibody specifically reacts with interleukin-18 receptor, exhibiting efficacy in purification, detection and inhibition of interleukin-18 receptor.Type: GrantFiled: August 29, 2000Date of Patent: July 29, 2003Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kakuji Torigoe, Shimpei Ushio, Toshio Kunikata, Masashi Kurimoto
-
Publication number: 20030133919Abstract: Disclosed are a polypeptide (including that in soluble form) as receptor for a novel cytokine, i.e., interleukin-18, a DNA encoding the polypeptide, and the uses of the polypeptide including pharmaceutical and neutralizer to interleukin-18. Pharmaceuticals with the polypeptide is useful to treat and prevent autoimmune and allergic disease because it suppresses and regulates excessive immunoreaction.Type: ApplicationFiled: January 23, 2003Publication date: July 17, 2003Applicant: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJOInventors: Kakuji Torigoe, Takanori Okura, Masashi Kurimoto
-
Publication number: 20030099607Abstract: A protein which induces the IFN-&ggr; production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.Type: ApplicationFiled: August 12, 1999Publication date: May 29, 2003Inventors: HARUKI OKMURA, TADAO TANIMOTO, KAKUJI TORIGOE, TOSHI KUNIKATA, MUTSUKO TANIGUCHI, KEIZO KOHNO, MASSASHI KURIMOTO
-
Patent number: 6559298Abstract: Disclosed are a polypeptide (including that in soluble form) as receptor for a novel cytokine, i.e., interleukin-18, a DNA encoding the polypeptide, and the uses of the polypeptide including pharmaceutical and neutralizer to interleukin-18. Pharmaceuticals with the polypeptide is useful to treat and prevent autoimmune and allergic disease because it suppresses and regulates excessive immunoreaction.Type: GrantFiled: April 24, 2000Date of Patent: May 6, 2003Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kakuji Torigoe, Takanori Okura, Masashi Kurimoto
-
Patent number: 6277598Abstract: A protein which induces the IFN-&ggr; production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein. Fragments of the protein can be used for production of antibodies, and can be produced recombinantly using appropriate medric acids, host cells and vectors. Fragments of nuclear acids may also be used as probes.Type: GrantFiled: February 19, 1999Date of Patent: August 21, 2001Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Haruki Okamura, Tadao Tanimoto, Kakuji Torigoe, Toshio Kunikata, Mutsuko Taniguchi, Keizo Kohno, Masashi Kurimoto
-
Patent number: 6274367Abstract: Disclosed is a DNA coding for mammalian L-asparaginase. Transformants introduced with the DNA effectively produce desired amounts of mammalian L-asparaginase such as those from humans, guinea pigs, and mice. The DNA is also useful as a probe for screening a DNA coding for desired mammalian L-asparaginase.Type: GrantFiled: May 11, 1999Date of Patent: August 14, 2001Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Takeshi Ario, Madoka Taniai, Kakuji Torigoe, Masashi Kurimoto
-
Patent number: 6274709Abstract: A protein which induces the IFN-&ggr; production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.Type: GrantFiled: February 19, 1999Date of Patent: August 14, 2001Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Haruki Okamura, Tadao Tanimoto, Kakuji Torigoe, Toshio Kunikata, Mutsuko Taniguchi, Keizo Kohno, Masashi Kurimoto
-
Patent number: 6214584Abstract: A polypeptide which has a molecular weight of 18,500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human in a relatively-high dose. It can be used to treat and/or prevent malignant tumors, viral diseases, bacterial infectious diseases, and immune diseases.Type: GrantFiled: April 8, 1997Date of Patent: April 10, 2001Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Shimpei Ushio, Kakuji Torigoe, Tadao Tanimoto, Haruki Okamura, Masashi Kurimoto